Skip to main content

Epitomics to Develop Antibodies for Mass Spec Assays in Support of CPTC


Antibody maker Epitomics this week announced that it has signed a contract with SAIC-Frederick to develop several dozen rabbit monoclonal antibodies to support the Clinical Proteomic Technologies for Cancer program.

The work will focus on developing antibodies to tryptic peptides derived from protein biomarkers in human plasma. The antibodies will be used for immuno-enrichment of target peptides in mass spec workflows like stable isotope standards and capture by anti-peptide antibodies, or SISCAPA, and immuno-MALDI mass spec.

Epitomics has completed the first phase of the project, which called for it to generate and affinity-purify polyclonal antibodies against the biomarkers. In the current phase it will generate monoclonal antibodies against biomarkers validated during Phase 1.

CPTC is a five-year, $104 million effort to develop proteomics tools and technologies to accelerate discovery and clinical research. In July SAIC-Frederick signed a deal with Precision Antibodies to provide antibody and antigen characterization of antibodies used in the CPTC initiative, which followed on a contract Precision won from SAIC-Frederick in 2009 to develop monoclonal antibodies for the program (PM 07/30/2010).

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.